ストックスクリーナーアプリを入手
1,027.51
1.80%
18.13
アフターアワーズ：
1029.44
1.93
+0.19%
Lilly Eli Co (LLY) 最新ニュース
Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next - ts2.tech
Clinical trials reveal promising results for new Eli Lilly drug - NewsNation
What's Going On With Eli Lilly Stock Friday?Eli Lilly (NYSE:LLY) - Benzinga
Eli Lilly to Build $6-Billion Alabama Facility - AdvancedManufacturing.org
Moody’s affirms Eli Lilly’s Aa3 rating, outlook revised to positive By Investing.com - Investing.com Nigeria
Eli Lilly (LLY) Reports Promising Results from Phase 3 EMBER-3 S - GuruFocus
Eli Lilly announces updated results from Phase 3 EMBER-3 study of Inluriyo - TipRanks
Exclusive: FDA leaders pushed to cut Lilly weight-loss pill review time - Reuters
Lilly shifts ambition for broader oral SERD label to largest oncology trial in company history - Fierce Pharma
Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win - Yahoo Finance
Eli Lilly touts strong results of new experimental weight loss drug retatrutide - Straight Arrow News
Eli Lilly Stock Rises After Late-Stage Data Shows Longer Survival With Breast Cancer Drug - Stocktwits
U.S. Regulators Pushed to Fast-Track Approval of Eli Lilly’s (LLY) Weight-Loss Pill: Reports - TipRanks
Eli Lilly (LLY) Gains EU Support for Mounjaro Use in Younger Pat - GuruFocus
EU committee backs extending use of Lilly's diabetes drug for children aged 10 and above - Reuters
Lilly's next-gen drug shows greater weight loss than Zepbound in late-stage trial - Reuters
Truist Securities reiterates Buy rating on Eli Lilly stock at $1,182 - Investing.com
Lilly to Invest $6B in New API Manufacturing Facility in Alabama - Contract Pharma
Eli Lilly Stock (NYSE: LLY) in Focus: Retatrutide’s Near-30% Weight-Loss Data, FDA Fast-Track Questions for Orforglipron, and Fresh Analyst Forecasts (Dec. 12, 2025) - ts2.tech
US FDA likely to speed up evaluation of Eli Lilly's weight loss pill - medwatch.com
Eli Lilly (LLY) Boosts Dividend by 15.3% - GuruFocus
FDA May Fast-Track Eli Lilly’s Weight Loss PillEli Lilly (NYSE:LLY) - Benzinga
Eli Lilly & Co: Promising Future with Strong TRIUMPH-4 Trial Results and Strategic Pipeline Driving Growth - TipRanks
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Dec 2025) - 24/7 Wall St.
Eli Lilly (LLY) Pushes for Faster FDA Review of Weight Loss Pill - GuruFocus
Think Eli Lilly is expensive? This metric says otherwise. - MSN
Top FDA brass said to have pushed for a faster review of Lilly’s weight loss pill - Seeking Alpha
Think Eli Lilly Is Expensive? This Metric Says Otherwise. - The Motley Fool
Exclusive-US FDA brass pushed internally for speedier Lilly weight-loss pill verdict - Yahoo
Lilly CEO talks innovation, ‘generational impact’ ahead of 150th anniversary - Inside INdiana Business
Eli Lilly to build $6 B worth API manufacturing facility in US - BioSpectrum Asia
A Decade of Rewards: $47 Bil From Eli Lilly Stock - Trefis
Lilly’s next-gen drug tops Zepbound on weight loss in late-stage trial - WHTC
Eli Lilly's Retatrutide Shows 28.7% Weight Loss in Phase 3 Trial - 조선일보
Oh no, Ozempic! Eli Lilly’s New Weight-Loss Drug KOs Rival Treatments - The Daily Upside
Eli Lilly Drug for 3 Obesity Targets Sets New High Bar for Weight Loss in a Clinical Trial - MedCity News
Pharmaceutical giant Lilly plans $6 billion advanced manufacturing plant in Huntsville, Alabama - Alabama Weather Network
Eli Lilly's $6B boost: New jobs, growth for Huntsville-Limestone County area - WAAY 31 News
Lilly’s Retatrutide Raises Weight-Loss Bar In First Phase III Readout - Citeline News & Insights
Eli Lilly's $6 billion boost means new jobs, growth for Huntsville-Limestone County area - WAAY 31 News
Eli Lilly's $6B boost: new jobs, growth for Limestone County - WAAY 31 News
Eli Lilly's next-gen obesity drug shows biggest weight loss yet in clinical trial - AOL.com
Eli Lilly (LLY) Stock After Hours on December 11, 2025: Retatrutide Breakthrough, $6B Plant — and What to Watch Before Friday’s Open - ts2.tech
Eli Lilly Puts Obesity Field 'On Notice' With Best Weight Loss - Investor's Business Daily
Stock Movers: Mosaic Company, Eli Lilly, Lululemon - Bloomberg.com
New Eli Lilly Drug Retatrutide Brought Major Weight Loss in Trial - The New York Times
S&P 500 Slips as Oracle’s AI Capex Shock Knocks Wind Out of Post-Fed Rally - Investing.com
Eli Lilly Reveals $6B Pharmaceutical Facility in Alabama - Thomasnet
Stock Movers: Eli Lilly, Gemini Space Station, Oracle - Bloomberg.com
Eli Lilly Says Trial of Weight-Loss Drug Retatrutide Yields Encouraging Results - marketscreener.com
Eli Lilly's (LLY) Retatrutide Surpasses Expectations in Weight L - GuruFocus
Premarket Movers Thursday Oracle Stock Drops Eli Lilly Surges Amazon Under Pressure - TECHi
Market Voices: Lilly's new obesity drug, Bessent, EQT's robotics move - Seeking Alpha
Eli Lilly’s Adverum Acquisition: What They Didn’t Say in the Press Release! - Smartkarma
Eli Lilly’s Weight Loss Superdrug Worked So Well During Trials, Some Quit Over Losing Too Much - Gizmodo
A better Ozempic? Eli Lilly’s new obesity drug cut weight by 23%, study finds - The Independent
Eli Lilly Stock Rises After New Obesity Drug Crushes Phase 3 Goa - GuruFocus
Eli Lilly Stock Rises After New Obesity Drug Crushes Phase 3 Goals - TradingView
Eli Lilly (LLY) Stock Is Up, What You Need To Know - Finviz
Eli Lilly (LLY) Shares Surge on Promising Retatrutide Phase 3 Re - GuruFocus
Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial - MSN
Lilly rises on “best-in-class” data for new weight loss therapy - Seeking Alpha
Lilly to build $6B weight-loss drug factory in Alabama - Manufacturing Dive
Eli Lilly’s (LLY) Newest Weight-Loss Drug Delivers Strong Results in Late-Stage Trial - TipRanks
Lilly’s Retatrutide Displays Positive Topline Results in Successful Phase III Trial - PharmExec.com
Major weight loss, pain relief seen with Eli Lilly's next-gen drug in late-stage trial - Fox Business
0.75%
0.29%
大文字化:
|
ボリューム (24 時間):